Species profile · FDA CVM July 2026 extract
Horse adverse-event record
According to FDA CVM openFDA filings as of July 2026 extract, 10,745 adverse-event reports span 55 horse breeds.
- #4 of 55
- by report volume (all species)
- 10,745
- adverse-event reports
- 55
- breeds in this species
- 10.3%
- death-coded share
The record at a glance
According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Horse ranks #4 of 55 by total reports (10,745) and #35 of 41 by death-coded share (10.3%). National dual: Dog is #1 of 55 species by total adverse-event reports (806,331) at death-coded share 4.3% (rank 38 of 41); separately, Quail is #1 highest death-coded share at 84.6% (report rank #32).
- 806,331
- Dog reports (#1)
- 84.6%
- Quail death share (#1)
- #4
- This species, reports of 55
- #35
- This species, death share of 41
Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Horse has 10,745 reports now versus 10,563 in that prior snapshot: 182 more (1.7%).
- Report change
- +182
- Death-coded reports
- +23
- Death-coded share
- +0.0 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Horse changesHorse breeds by report volume
Exclusive partition of the 55 horse breed rows with adverse-event aggregates. Parts sum to this species' breed total.
Where Horse sits among species by death-coded share
COUNT-derived placement among 20 species with at least 50 FDA CVM reports. Death-coded share is exposure in the file, not a proven species risk rate.
Horse death-coded share vs every floor-qualified species
Death-coded share of FDA CVM reports · species with ≥50 reports (July 2026 extract)
10% 15th percentile Higher share than 15% of 20 indexed species
Each bar is a band; taller bars hold more indexed species. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source FDA Center for Veterinary Medicine · openFDA animal-and-veterinary adverse-event reports · July 2026 extract
Top Reactions
Most Referenced Drugs
Outcome Breakdown
Reports by Year
Horse Adverse Event Insights
The FDA Center for Veterinary Medicine database holds 10,745 adverse event reports for Horse, distributed across 55 distinct breeds currently tracked in the system. Of those reports, 1,107 involved a death outcome, producing a 10.3% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.
The most frequently reported clinical signs for Horse are Lack of efficacy - NOS (1,338 reports), Injection site swelling (793 reports), INEFFECTIVE, GASTRIC ULCER(S) (762 reports), Colic (731 reports), with Lack of efficacy - NOS leading the reaction traffic at 1,338 submissions. On the product side, Omeprazole is the single most-referenced drug with 1,502 reports, followed by Pergolide Mesylate (1,163), Ceftiofur Crystalline Free Acid (881), Ivermectin(1.55%)/Praziquantel(7.75%) Paste (629). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species, a useful starting point when comparing Horse reporting patterns against other companion animals in the dataset.
Of the 9,624 Horse reports with a coded outcome, Recovered/Normal accounts for the largest share at 37.0%. Annual submission volume spans 137 to 863 reports across the 17 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 55 tracked horse breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling, causation requires clinical investigation beyond what these aggregates can provide.
Horse Breeds (55)
| # | Breed | Reports | Deaths | Death Rate | Avg Age |
|---|---|---|---|---|---|
| 1 | Quarter Horse | 2,526 | 280 | 11.1% | 12.6 yr |
| 2 | Horse (unknown) | 2,370 | 237 | 10.0% | 13.8 yr |
| 3 | Thoroughbred | 1,222 | 100 | 8.2% | 12.0 yr |
| 4 | Warmblood (unspecified) | 541 | 38 | 7.0% | 12.8 yr |
| 5 | Arab | 467 | 45 | 9.6% | 16.9 yr |
| 6 | Paint | 386 | 53 | 13.7% | 14.3 yr |
| 7 | Horse (other) | 296 | 29 | 9.8% | 11.6 yr |
| 8 | Crossbred Equine/horse | 190 | 15 | 7.9% | 14.3 yr |
| 9 | Tennessee Walking Horse | 186 | 24 | 12.9% | 14.8 yr |
| 10 | Warmblood - Dutch | 184 | 5 | 2.7% | 12.1 yr |
| 11 | Appaloosa | 167 | 17 | 10.2% | 15.9 yr |
| 12 | Miniature | 164 | 26 | 15.9% | 12.1 yr |
| 13 | Pony (unspecified) | 151 | 18 | 11.9% | 18.3 yr |
| 14 | Morgan | 145 | 15 | 10.3% | 16.6 yr |
| 15 | Standardbred (unspecified) | 141 | 21 | 14.9% | 8.8 yr |
| 16 | Hanovarian | 137 | 3 | 2.2% | 12.9 yr |
| 17 | Mixed (Horse) | 103 | 16 | 15.5% | 6.3 yr |
| 18 | Saddlebred - American | 94 | 15 | 16.0% | 14.6 yr |
| 19 | Oldenburg | 71 | 2 | 2.8% | 10.6 yr |
| 20 | Mustang | 67 | 7 | 10.4% | 13.1 yr |
| 21 | Friesian | 52 | 4 | 7.7% | 11.9 yr |
| 22 | Percheron | 52 | 6 | 11.5% | 15.5 yr |
| 23 | Holsteiner | 48 | 2 | 4.2% | 13.5 yr |
| 24 | Paso Fino | 43 | 1 | 2.3% | 16.6 yr |
| 25 | Trakehner | 43 | 3 | 7.0% | 15.9 yr |
| 26 | Belgian Draft, also called Brabant or Brabants trekpaard | 41 | 5 | 12.2% | 13.6 yr |
| 27 | Welsh Pony | 37 | 1 | 2.7% | 11.1 yr |
| 28 | Rocky Mountain Horse | 36 | 3 | 8.3% | 14.8 yr |
| 29 | Pony of the Americas | 33 | 7 | 21.2% | 18.2 yr |
| 30 | Shetland Pony | 33 | 7 | 21.2% | 17.7 yr |
| 31 | Pura Raza Española (Andalusian) | 32 | 3 | 9.4% | 11.2 yr |
| 32 | Welsh Mountain Pony | 31 | 3 | 9.7% | 16.2 yr |
| 33 | Irish Cob (Tinker) | 31 | 1 | 3.2% | 9.8 yr |
| 34 | Standardbred - American | 29 | 12 | 41.4% | 4.8 yr |
| 35 | Haflinger | 24 | 6 | 25.0% | 12.3 yr |
| 36 | Welsh Cob | 22 | 4 | 18.2% | 14.8 yr |
| 37 | Palomino | 22 | 3 | 13.6% | 14.5 yr |
| 38 | Icelandic Pony | 20 | 2 | 10.0% | 14.2 yr |
| 39 | Missouri Fox Trotting Horse | 19 | 1 | 5.3% | 20.1 yr |
| 40 | Clydesdale | 19 | 5 | 26.3% | 8.3 yr |
| 41 | Lusitano | 15 | 2 | 13.3% | 11.2 yr |
| 42 | Shire | 14 | 4 | 28.6% | 13.6 yr |
| 43 | Irish Hunter | 12 | 0 | 0.0% | 10.8 yr |
| 44 | Connemara Pony | 12 | 1 | 8.3% | 13.4 yr |
| 45 | Peruvian Paso | 12 | 1 | 8.3% | 15.4 yr |
| 46 | Warmblood - Belgian | 8 | 0 | 0.0% | 11.2 yr |
| 47 | Trotter - French | 7 | 0 | 0.0% | 16.4 yr |
| 48 | Lippizzaner | 7 | 3 | 42.9% | 19.7 yr |
| 49 | Mule not Specified | 7 | 3 | 42.9% | 15.5 yr |
| 50 | Warmblood - Danish | 6 | 0 | 0.0% | 8.4 yr |
| 51 | Pinto | 6 | 2 | 33.3% | 12.4 yr |
| 52 | Selle Français | 5 | 0 | 0.0% | 14.7 yr |
| 53 | Draught (unspecified) | 5 | 0 | 0.0% | 11.6 yr |
| 54 | Warmblood - Swedish | 5 | 0 | 0.0% | 14.4 yr |
| 55 | Hackney | 5 | 1 | 20.0% | 15.7 yr |
What to do with horse data
- Look up any horse breed's report volume and death-coded share in the full breed directory. Browse breeds
- Read how death-coded share differs from a mortality rate before drawing conclusions. Breed-specific risks guide
- See how species compare nationwide by report volume and death-coded share. Rankings
A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.
Read our methodology - how this data is sourced, computed, and verified.
Related
According to the FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Event extract, every figure on this page is rendered from that public file; no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.